Fig. 4

Higher susceptibility to EAMG of miR-29a/b-1 heterozygous mice.

C57BL/6 WT and miR-29a/b-1 HET mice were immunized with CFA/T-AChR or just CFA (for a group of WT mice) at day 0 and boosted at day 30 (as indicated with arrows in a). Clinical evaluations were done at days 0, 14, 28, and 42. A global clinical score was calculated for each mouse taking into account the weight loss, the grip test, and the inverted grid test, as detailed in the method section. a Mean of global clinical scores was calculated for each mouse group (±SEM) and showed in kinetic. Data were analyzed by the two-way ANOVA test and p values determined with Bonferroni posttests. p values are indicated if significant with grey asterisks for WT/T-AChR and HET/T-AChR as compared to WT/CFA, and with bleu asterisks for HET/T-AChR as compared to WT/T-AChR. b Global clinical scores were given for each mice at the end of the experiment (day 42). c, d Anti-T-AChR antibodies were measured by ELISA and detected with anti-mouse IgG (c), IgG2b (d), IgG2c (e), or IgG1 (f) antibodies. Relative affinity index of anti-AChR IgG antibodies was determined using KSCN thiocyanate as detailed in the methods (g). b–g p values were assessed by the Mann-Whitney test. Male mice are represented with grey dots